Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinN (3)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 31 - 40 records in total 72
    records per page




    Clinical Characteristics and Prognosis of Patients with COVID-19 MESHD Combineded with or without Diabetes, Hypertension or Coronary

    Authors: Haoxiang Li; Jianguo Zhang; Jinhui Zhang; Ling Yang; Dong Wang; Li Zhao; Xia Deng; Guoyue Yuan

    doi:10.21203/rs.3.rs-36840/v1 Date: 2020-06-19 Source: ResearchSquare

    Bcakground: This study was to investigate the clinical characteristics and prognosis of COVID-19 MESHD patients combined with or without major chronic diseases MESHD like diabetes MESHD, hypertension MESHD or coronary. Methods: We retrospectively analyzed 183 patients with COVID-19 MESHD diagnosed at First People's Hospital of Jiangxia District (FPHJD) in Wuhan, China attended by Affiliated Hospital of Jiangsu University supporting medical team from February 1, 2020 to March 15, 2020. Patients were divided into simple COVID-19 MESHD group(n=134), COVID-19 MESHD combined with diabetes MESHD, hypertension MESHD or coronary group(n=49). Besides, COVID-19 MESHD patients with diabetes MESHD, hypertension MESHD or coronary were further classified into severe pneumonia MESHD group(n=23) and common pneumonia MESHD group(n=26), death MESHD group(n=17) and survival group(n=32). The prognosis of COVID-19 MESHD patients was evaluated by analyzing the clinical data and the results of laboratory tests. Results: 183 patients were included in this study, of whom 166 were discharged and 16 died in hospital. 49 (26.92%) patients had a comorbidity, with hypertension MESHD being the most common [37 (20.33%) patients], followed by diabetes MESHD [25 (13.74%) patients] and coronary heart disease MESHD [4 (2.2%) patients]. Compared with simple COVID-19 MESHD group, the proportion of history of chronic respiratory system disease MESHD, age, D-dimer, procalcitonin, C-reactive protein HGNC, myoglobin HGNC, cardiac troponin I, creatine kinase MB, lactate dehydrogenase, white blood cell count, neutrophil count, neutrophil percentage, blood urea nitrogen, creatinine and mortality rate were significantly higher in COVID-19 MESHD combined with chronic diseases group, whereas lymphocyte count, lymphocyte percentage and alanine transferase were significantly lower in COVID-19 MESHD combined with chronic diseases group. Among COVID-19 MESHD patients with chronic diseases MESHD, D-dimer, procalcitonin, C-reactive protein, myoglobin, cardiac troponin I, lactate dehydrogenase, white blood cell count, neutrophil count, neutrophil percentage, blood urea nitrogen, death MESHD rate was significantly higher in severe pneumonia MESHD group than common pneumonia group. While lymphocyte count and lymphocyte percentage were significantly lower in severe pneumonia MESHD group than common pneumonia group. Besides, we found that the proportion of history of chronic respiratory system disease MESHD, D-dimer, procalcitonin, myoglobin HGNC, cardiac troponin I, creatine kinase MB, lactate dehydrogenase, neutrophil count, neutrophil percentage, blood urea nitrogen were significantly higher in death group compared with survival group, whereas lymphocyte count and lymphocyte percentage were significantly lower in survival group. In COVID-19 MESHD combined with chronic diseases group, univariate logistic regression showed that the risk for severe pneumonia MESHD were D-dimer, C-reactive protein HGNC, lactate dehydrogenase, white blood cell count, neutrophil count and neutrophil percentage. Univariate logistic regression also showed that the risk for death MESHD were D-dimer, lactate dehydrogenase, white blood cell count, neutrophil count, neutrophil percentage and blood urea nitrogen. Multivariate regression logistic showed that lactate dehydrogenase were independent risk factors for death among COVID-19 MESHD patients combined with chronic diseases MESHD. Cox regression analysis showed that compared with simple COVID-19 MESHD group, the RR(95% CI) in COVID-19 MESHD patients combined with diabetes MESHD, hypertension MESHD, and coronary were 2.187 (1.141~4.191) for death MESHD (P<0.05). Conclusion: Among COVID-19 MESHD patients combined with diabetes MESHD, hypertension MESHD or coronary, the risk factors for severe pneumonia MESHD were D-dimer, C-reactive protein HGNC, lactate dehydrogenase, white blood cell count, neutrophil count and neutrophil percentage, whereas the risk factors for death MESHD were D-dimer, lactate dehydrogenase, white blood cell count, neutrophil count, neutrophil percentage and blood urea nitrogen. Moreover, lactate dehydrogenase were independent risk factors for death MESHD. The mortality rate of COVID-19 MESHD patients combined with diabetes MESHD, hypertension MESHD or coronary was higher than that of simple COVID-19 MESHD patients.

    Comparative Survival Analysis of Immunomodulatory Therapy for COVID-19 MESHD 'Cytokine Storm': A Retrospective Observational Cohort Study

    Authors: Sonali Narain; Dimitre Stefanov; Alice S Chau; Andrew G Weber; Galina S Marder; Blanka Kaplan; Prashant Malhotra; Ona Bloom; Audrey Liu; Martin Lesser; Negin Hajizadeh

    doi:10.1101/2020.06.16.20126714 Date: 2020-06-19 Source: medRxiv

    BackgroundCytokine storm is a marker of COVID-19 MESHD illness severity and increased mortality. Immunomodulatory treatments have been repurposed to improve mortality outcomes. MethodsWe conducted a retrospective analysis of electronic health records across the Northwell Health system. COVID-19 MESHD patients hospitalized between March 1, 2020 and April 15, 2020, were included. Cytokine storm was defined by inflammatory markers: ferritin >700ng/mL, C-reactive protein HGNC >30mg/dL, or lactate dehydrogenase >300U/L. Patients were subdivided into six groups -no immunomodulatory treatment (standard of care) and five groups that received either corticosteroids, anti- interleukin 6 HGNC ( IL-6 HGNC) antibody (tocilizumab) or anti- IL-1 HGNC therapy (anakinra) alone or in combination with corticosteroids. The primary outcome was hospital mortality. ResultsThere were 3,098 patients who met inclusion criteria. The most common comorbidities were hypertension MESHD (40-56%), diabetes MESHD (32-43%) and cardiovascular disease MESHD (2-15%). Patients most frequently met criteria with high lactate dehydrogenase (74.8%) alone, or in combination, followed by ferritin (71.4%) and C-reactive protein HGNC (9.4%). More than 80% of patients had an elevated D-dimer. Patients treated with a combination of tocilizumab and corticosteroids (Hazard Ratio [HR]: 0.459, 95% Confidence Interval [CI]: 0.295-0.714; p<0.0001) or corticosteroids alone (HR: 0.696, 95% CI: 0.512-0.946; p=0.01) had improved hospital survival compared to standard of care. Corticosteroids and tocilizumab was associated with increased survival when compared to corticosteroids and anakinra (HR: 0.612, 95% CI: 0.391-0.958; p-value=0.02). ConclusionsWhen compared to standard of care, corticosteroid and tocilizumab used in combination, or corticosteroids alone, was associated with reduced hospital mortality for patients with COVID-19 MESHD cytokine storm.

    Impact of diabetes on COVID-19 MESHD-related in-hospital mortality: a retrospective study from Northern Italy

    Authors: Stefano Ciardullo; Francesca Zerbini; Silvia Perra; Emanuele Muraca; Rosa Cannistraci; Marinella Lauriola; Paolo Grosso; Guido Lattuada; Giovanbattista Ippoliti; Andrea Mortara; Giuseppina Manzoni; Gianluca Perseghin

    doi:10.21203/rs.3.rs-36391/v1 Date: 2020-06-18 Source: ResearchSquare

    Purpose. The purpose of this study was to evaluate the impact of pre-existing diabetes MESHD on in-hospital mortality in patients admitted for Coronavirus Disease 2019 MESHD ( COVID-19 MESHD).Methods. This is a single center, retrospective study conducted at Policlinico di Monza hospital, located in the Lombardy region, Northern Italy. We reviewed medical records of 373 consecutive adult patients who were hospitalized with COVID-19 MESHD between February 22 and May 15, 2020. Data were collected on diabetes MESHD status, comorbid conditions and laboratory findings. Multivariable logistic regression was performed to evaluate the effect of diabetes MESHD on in-hospital mortality after adjustment for potential confounding variables.Results. Mean age of the patients was 72 ± 14 years (range 17-98), 244 (65.4%) were male and 69 (18.5%) had diabetes MESHD. The most common comorbid conditions were hypertension MESHD (237 [64.8%]), cardiovascular disease MESHD (140 [37.7%]) and malignant neoplasms MESHD (50 [13.6%]). In-hospital death occurred in 142 (38.0%) patients. In the multivariable model older age (Odds Ratio [OR] 1.07 [1.04-1.10] per year), diabetes MESHD (OR 2.2 [1.10-4.73]), chronic obstructive pulmonary disease MESHD (OR 3.30 [1.22-8.90]), higher values of lactic dehydrogenase and C-reactive protein HGNC were independently associated with in-hospital mortality.Conclusion. In this retrospective single-center study, diabetes MESHD was independently associated with a higher in-hospital mortality. More intensive surveillance of patients with this condition is to be warranted.

    Corona Virus Disease 2019 ( COVID-19 MESHD): Intensive Care Admission Prediction Model

    Authors: Mahomood Y. Hachim; Ibrahim Y. Hachim; Kashif Bin Naeem; Haifa Hannawi; Issa Al Salmi; Suad Hannawi

    doi:10.21203/rs.3.rs-35442/v1 Date: 2020-06-14 Source: ResearchSquare

    Background: Identifying clinical-features or a scoring-system to predict a benefit from hospital admission for patients with COVID-19 MESHD can be of great value for the decision-makers in the health-sector. We aim to identify differences in patients' demographic, clinical, laboratory and radiological findings of COVID-19 MESHD positive cases to develop and validate a diagnostic-model predicting who will develop severe-form and who will need critical-care in the future.Methodology: Patients were classified according to their clinical state into mild, moderate, severe, and critical. All their baseline clinical data, laboratory, and radiological results were used to construct a prediction-model that can predict if the COVID-19 MESHD patients will develop a severe condition that will necessitate their ICU-admission. An ensemble feature selection tool was used to identify the relative importance of each variable. The performance of the selected features compared to all features using logistic regression and area under curve test.Results: Patients with ICU admission showed a distinct clinical, demographic as well as laboratory features when compared to pattients that did not need ICU admission. This includes elder age group, male gender and presence of comorbidities like diabetis and history of hypertension MESHD.Out of the different demographic, clinical and laboratory charasteristics of these patients, Age at diagnosis, Lymphocyte count, C-reactive protein HGNC ( CRP HGNC), lactate dehydrogenase (LDH), Albumin HGNC, Urea, and Procalcitonin levels were found to be able to predict which patients may need ICU admission. Conclusion: Higher CRP HGNC, LDH, Age at diagnosis, Urea, Procalcitonin, and lower Albumin HGNC, Lymphocyte count are significant determinant in ICU admission for COVID-19 MESHD patients. 

    COVID-19 MESHD patients with hypertension under potential risk of worsened organ injuries

    Authors: Fei Xia; Mingwei Zhang; Bo Cui; Wei An; Min Chen; Ping Yang; Tao Qin; Xiaoyang Zhou; Yaling Liao; Xin Xu; Shiguo Liu; Kuangyu Li; Qin Zhou; Keke Wang; Guangxu Hu; Ming Du; Songrui Chen; Jianjun Zhang; Yafang Zhang; Wei Wei; Ming Xiang

    doi:10.21203/rs.3.rs-34615/v1 Date: 2020-06-11 Source: ResearchSquare

    COVID -19 has rapidly spread from Wuhan to worldwide, and now has become a global health concern. Hypertension MESHD is the most common chronic illness in COVID-19 MESHD, while the influence on those patients have not been well described. In this retrospective study, 82 confirmed patients with COVID-19 MESHD were enrolled, with epidemiological, demographic, clinical, laboratory, radiological, and therapies data analyzed and compared between COVID-19 MESHD patients with (29 cases) or without (53 cases) hypertension MESHD. Of all 82 patients with COVID-19 MESHD, the median age of all patients was 60.5 years, including 49 females (59.8%) and 33 (40.2%) males. Hypertension MESHD (31[28.2%]) was the most chronic illness, followed by diabetes MESHD (16 [19.5%]) and cardiovascular disease MESHD (15 [18.3%]). Common symptoms included fatigue (55[67.1%]), dry cough (46 [56.1%]) and fever (≥37.3℃ (46 [56.1%]). The median time from illness onset to positive outcomes of RT-PCR analysis were 13.0 days, ranging from 3-25 days. In hypertension group, 6 (20.7%) patients died compared to 5 (9.4%) died in non-hypertension group. More hypertension patients with COVID-19 MESHD (8 [27.6%]) had at least one coexisting disease than those of non-hypertension patients (2 [3.8%]) (P=0.002). Compared with non-hypertension patients, higher levels of neutrophil counts, serum amyloid A, C-reactive protein HGNC, and NT-proBNP were observed in hypertension group, whereas levels of lymphocyte count and eGFR HGNC were decreased. Dynamic observations displayed more significant and worsened outcomes in hypertension group after hospital admission. COVID-19 MESHD patients with hypertension take more risks of severe inflammatory reactions, worsened internal organ injuries, and deteriorated progress. 

    Level of the SARS-CoV-2 receptor ACE2 HGNC is highly elevated in old-aged patients with aortic stenosis: implications for ACE2 HGNC as a biomarker for the severity of COVID-19 MESHD

    Authors: Miklós Fagyas; Attila Kertész; Ivetta Siket Mányiné; Viktor Bánhegyi; Bertalan Kracskó; Andrea Szegedi; Miklós Szokol; Gusztáv Vajda; Ildikó Rácz; Zoltán Csanádi; Zoltán Papp; Attila Tóth; Sándor Sipka

    doi:10.21203/rs.3.rs-34549/v1 Date: 2020-06-10 Source: ResearchSquare

    Coronavirus disease 2019 MESHD ( COVID-19 MESHD) has a high mortality in elderly patients with pre- existing cardiovascular diseases MESHD. The cellular receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the angiotensin converting enzyme 2 ( ACE2 HGNC), thereby implicating a link between cardiovascular diseases MESHD and SARS-CoV-2 susceptibility. Aortic stenosis MESHD (AS) represents a chronic inflammatory state with severe cardiovascular complications MESHD in the elderly, a prime condition for COVID-19 MESHD mortality. The circulating ACE2 HGNC levels were measured in 111 patients with severe AS and compared to patients with hypertension MESHD and healthy individuals.About 4-times higher circulating ACE2 HGNC activity was found in patients with severe AS than in hypertensives MESHD or healthy individuals (103.4±5.4, n=111, 24.4±0.6, n=540 and 17.3±1.3±0.6 mU/L, n=46, respectively). Patients with severe AS were older than patients with hypertension MESHD (79±0.7 years vs. 60±0.5 years, P<0.05). Serum ACE2 HGNC activity correlated negatively with the left ventricular ejection fraction and positively with the right ventricular systolic pressure in patients with AS. In contrast, circulating ACE2 HGNC activity was independent of the blood pressure, characteristics of the stenotic aortic valve (aortic valve area, peak flow velocity), kidney function (GFR) and inflammatory state ( CRP HGNC). We found no effect of RAAS inhibitory drugs on the serum ACE2 HGNC activity in this group of patients.Our results illustrate circulating ACE2 HGNC as a potential interface between chronic inflammation MESHD, cardiovascular disease MESHD and COVID-19 MESHD susceptibility. Elderly patients with AS have markedly elevated ACE2 HGNC levels together with altered left and right ventricular functions, which may pose higher risks during COVID-19 MESHD. Our clinical data do not support a role for RAAS inhibitors in regulating circulating ACE2 HGNC levels.

    What is the clinical course of patients hospitalised for COVID-19 MESHD treatment Ireland: a retrospective cohort study in Dublin’s North Inner City (the ‘Mater 100’)

    Authors: Brendan O’Kelly*; Colm Cronin*; Stephen Peter Connolly*; Walter Cullen; Gordana Avramovic; Tina McHugh; Eileen O’Connor; Aoife Cotter; Peter Doran; Tara McGinty; Dermot O’Callaghan; Sean Gaine; Gerard Sheehan; Eamonn Brazil; Brian Marsh; John S. Lambert

    doi:10.21203/rs.3.rs-34035/v1 Date: 2020-06-08 Source: ResearchSquare

    Background: Since March 2020, Ireland has experienced an outbreak of coronavirus disease 2019 MESHD ( COVID-19 MESHD), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, while several cohorts from China have been described, our understanding is limited, with no data describing the epidemiological and clinical characteristics of patients with COVID-19 MESHD in Ireland. To improve our understanding of the clinical characteristics of this emerging infection we carried out a retrospective review of patient data to examine the clinical characteristics of patients admitted for COVID-19 MESHD hospital treatment.Methods: Demographic, clinical and laboratory data on the first 100 adult patients admitted to Mater Misericordiae University Hospital (MMUH) for in-patient COVID-19 MESHD treatment after onset of the outbreak in March 2020 was extracted from clinical and administrative records. Missing data were excluded from the analysis.Results: Fifty-eight per cent were male, 63% were Irish nationals, 29% were GMS eligible, and median age was 45 years (interquartile range [IQR] =34-64 years). Patients had symptoms for a median of five days before diagnosis (IQR=2.5-7 days), most commonly cough (72%), fever MESHD (65%), dyspnoea MESHD (37%), fatigue MESHD (28%), myalgia MESHD (27%) and headache MESHD (24%). Of all cases, 54 had at least one pre-existing chronic illness (most commonly hypertension MESHD, diabetes mellitus MESHD or asthma MESHD). At initial assessment, the most common abnormal findings were: C-reactive protein HGNC >7.0mg/L (74%), ferritin >247μg/L (women) or >275μg/L (men) (62%), D-dimer >0.5μg/dL (62%), chest imaging (59%), NEWS Score (modified) of ≥3 (55%) and heart rate >90/min (51%). Twenty-seven required supplemental oxygen, of which 17 were admitted to the intensive care unit - 14 requiring ventilation. Forty received antiviral treatment (most commonly hydroxychloroquine or lopinavir/ritonavir). Four died, 17 were admitted to intensive care, and 74 were discharged home, with nine days the median hospital stay (IQR=6-11).Conclusion: Our findings reinforce the emerging consensus of COVID-19 MESHD as an acute life-threatening disease and highlights, the importance of laboratory (ferritin, C-reactive protein HGNC, D-dimer) and radiological parameters, in addition to clinical parameters. Further cohort studies involving larger samples followed longitudinally are a priority.

    A tertiary center experience of multiple myeloma patients with COVID-19 MESHD: lessons learned and the path forward

    Authors: Bo Wang; Oliver Van Oekelen; Tarek Mouhieddine; Diane Marie Del Valle; Joshua Richter; Hearn Jay Cho; Shambavi Richard; Ajai Chari; Sacha Gnjatic; Miriam Merad; Sundar Jagannath; Samir Parekh; Deepu Madduri

    doi:10.1101/2020.06.04.20122846 Date: 2020-06-05 Source: medRxiv

    Background: The COVID-19 pandemic MESHD COVID-19 pandemic MESHD, caused by SARS-CoV-2 virus, has resulted in over 100,000 deaths in the United States. Our institution has treated over 2,000 COVID-19 MESHD patients during the pandemic in New York City. The pandemic directly impacted cancer MESHD patients and the organization of cancer MESHD care. Mount Sinai Hospital has a large and diverse multiple myeloma MESHD ( MM MESHD) population. Herein, we report the characteristics of COVID-19 MESHD infection and serological response in MM MESHD patients in a large tertiary care institution in New York. Methods: We performed a retrospective study on a cohort of 58 patients with a plasma-cell disorder (54 MM MESHD, 4 smoldering MM MESHD) who developed COVID-19 MESHD between March 1 HGNC, 2020 and April 30, 2020. We report epidemiological, clinical and laboratory characteristics including persistence of viral detection by polymerase chain reaction (PCR) and anti-SARS-CoV-2 antibody testing, treatments initiated, and outcomes. Results: Of the 58 patients diagnosed with COVID-19 MESHD, 36 were hospitalized and 22 were managed at home. The median age was 67 years; 52% of patients were male and 63% were non-white. Hypertension MESHD (64%), hyperlipidemia MESHD (62%), obesity MESHD (37%), diabetes mellitus MESHD (28%), chronic kidney disease MESHD (24%) and lung disease MESHD (21%) were the most common comorbidities. In the total cohort, 14 patients (24%) died. Older age (>70 years), male sex, cardiovascular risk, and patients not in complete remission (CR) or stringent CR were significantly (p<0.05) associated with hospitalization. Among hospitalized patients, laboratory findings demonstrated elevation of traditional inflammatory markers ( CRP HGNC, ferritin, D-dimer) and a significant (p<0.05) association between elevated inflammatory markers, severe hypogammaglobulinemia MESHD, non-white race, and mortality. Ninety-six percent (22/23) of patients developed antibodies to SARS-CoV-2 at a median of 32 days after initial diagnosis. Median time to PCR negativity was 43 (range 19-68) days from initial positive PCR. Conclusions: Drug exposure and MM MESHD disease status at the time of contracting COVID-19 MESHD had no bearing on mortality. Mounting a severe inflammatory response to SARS-CoV-2 and severe hypogammaglobulinemia MESHD were associated with higher mortality. The majority of patients mounted an antibody response to SARS-CoV-2. These findings pave a path to identification of vulnerable MM MESHD patients who need early intervention to improve outcome in future outbreaks of COVID-19 MESHD.

    CONUT score is associated with mortality in patients with COVID-19 MESHD: a retrospective study in Wuhan

    Authors: Ruoran Wang; Min He; Jirong Yue; Lang Bai; Dan Liu; Zhixin Huang; Ting Zhu; Yan Kang

    doi:10.21203/rs.3.rs-32889/v1 Date: 2020-06-01 Source: ResearchSquare

    Background The coronavirus disease 2019 MESHD ( COVID-19 MESHD) pneumonia MESHD, outbreak in Wuhan, China, has led to a global pandemic. The high mortality of COVID-19 MESHD patients makes it significant to evaluate possible disease progression. This study was designed to explore the prognostic value of Controlling Nutritional Status (CONUT) score in patients with COVID-19 MESHD.Methods Patients diagnosed with COVID-19 MESHD of a single center in Wuhan, China from January 2020 to February 2020 were enrolled in this study. Logistic regression analysis was performed to find independent risk factor of mortality. Receiver operating characteristics (ROC) curve was drawn to evaluate the prognostic value of CONUT score.Results Among 442 included patients, there were 79 non-survivors with mortality of 17.9%. Compared with survivors, the median age (p < 0.001) and male ratio (p = 0.042) were higher in non-survivors. Non-survivors had higher incidence of comorbidities including hypertension MESHD (p < 0.001), chronic lung disease MESHD (p = 0.001) and cardiovascular disease MESHD (p = 0.005). Complications such as respiratory failure MESHD(p < 0.001), acute kidney injury MESHD ( AKI MESHD) (p < 0.001) occurred more frequently in non-survivors. Multivariate logistic regression analysis showed that CONUT (p = 0.002), lactate dehydrogenase (LDH) (p < 0.001), C-reactive protein HGNC ( CRP HGNC) (p = 0.020) were risk factor of mortality in COVID-19 MESHD patients. Area under the ROC curve (AUC) of CONUT and Nutrition risk screening 2002 (NRS2002) score were 0.813 and 0.795, respectively. Comprised of CONUT, LDH, CRP HGNC, the constructed prognostic model had higher AUC of 0.923 (Z = 3.5210, p < 0.001).Conclusion CONUT is an independent risk factor of mortality in COVID-19 MESHD patients. Evaluating CONUT is beneficial for clinicians to predict the progression of COVID-19 MESHD patients and strengthen monitoring and management to improve prognosis.

    Comparison of the Clinical Characteristics of Patients With COVID-19 MESHD in Suining and Wuhan

    Authors: Xiao-juan Wu; Chao-Ping Wang; Xiao-Bin Luo; Gao-Yan He; Bao-Lin Jia; Jing Wang; Li Luo; Rong Qiu; Zheng-Guang He; Min-Chao Li

    doi:10.21203/rs.3.rs-32683/v1 Date: 2020-05-30 Source: ResearchSquare

     Background Coronavirus disease 2019 MESHD ( COVID-19 MESHD), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first identified in December 2019 in Wuhan. This study mainly analyzed the clinical characteristics, imaging features, and prognosis of patients with COVID-19 MESHD in Suining, one of China's fourth-tier cities, and Wuhan in 2019 and compared data between the 2 cities. Methods A retrospective analysis of the epidemiological history, clinical data, symptom presentation, laboratory test results, chest computed tomography (CT) imaging features, treatment measures and prognosis of 68 patients with COVID-19 MESHD diagnosed at Wuhan Red Cross Hospital and 17 patients with COVID-19 MESHD diagnosed at Suining Central Hospital from January 23, 2020, to February 27, 2020, was conducted. Results 1) The incidence rate of COVID-19 MESHD in Wuhan was 52.99‱, and the incidence rate in Suining was 0.04‱. The median age of patients with COVID-19 MESHD was 40.71 years old in Suining and 56.04 years old in Wuhan. The age of patients with COVID-19 MESHD in Wuhan was significantly older than that of patients with COVID-19 MESHD in Suining. Among the 68 patients with COVID-19 MESHD in Wuhan, 30 (44.1%) had hypertension MESHD, and 25 (36.8%) had diabetes MESHD. Three out of the 17 patients in Suining (17.6%) had hypertension MESHD, and 2 patients (11.8%) had diabetes MESHD. The proportion of patients with diabetes MESHD or hypertension MESHD in Wuhan was significantly higher than that in Suining (P<0.05). In the clinical classification, there were 1 (5.9%) and 23 (33.8%) patients with severe COVID-19 MESHD in Suining and Wuhan, respectively. The proportion of patients with severe COVID-19 MESHD in Wuhan was significantly higher than that in Suining (P<0.05). Fever MESHD and cough MESHD were the most common clinical symptoms, with 9 cases (52.9%) and 8 cases (47.1%) in Suining, respectively, and 54 cases (79.4%) and 42 cases (61.8%) in Wuhan, respectively. There was 1 patient (5.9%) with COVID-19 MESHD with dyspnea MESHD in Suining and 23 patients (33.8%) with COVID-19 MESHD with dyspnea MESHD in Wuhan; the difference was statistically significant (P<0.05). Chest CT showed that lung consolidation occurred in 2 (11.8%) and 26 (38.2%) patients with COVID-19 MESHD in Suining and Wuhan, respectively. The proportion of lung consolidation in patients in Wuhan was significantly higher than that in patients in Suining (P<0.05). The laboratory tests suggested that percentage ofelevated C-reactive protein HGNC ( CRP HGNC) (58.8%), ALT (33.8%), blood glucose (45.6%), creatine kinase (CK) (33.8%) or D-dimer (47.1%) of patients in Wuhan were significantly increased than those in Suining (29.4%, 5.9%, 17.6%, 5.9%, and 17.7%, respectively). Moreover, the average length of hospital stay of patients in Wuhan was 17.49 days, which was significantly longer than that of patients in Suining (12.29 days). Conclusions The incidence of COVID-19 MESHD in fourth-tier cities, Suining, in China was significantly lower than that in Wuhan, and the disease severity was generally lower than that in Wuhan, with mostly good prognoses. Advanced age, diabetes MESHD, and hypertension MESHD are important factors that aggravate COVID-19 MESHD, while elevated CRP HGNC, ALT, blood glucose, CK, and D-dimer levels are important indicators for severe disease. 

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.